Skip to main content
OpenTrials
Completed

NCT Number: NCT00272948

Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide

The aim of this trial is to evaluate whether the prophylactic use of Defibrotide (DF) in pediatric patients (age less than 18 years) undergoing stem cell transplantation and who are at high risk of developing hepatic Veno-occlusive Disease (VOD) will have an impact on the incidence and severity of the disease. Patients will be randomly assigned to one of two treatment arms: Those allocated to the Prophylactic Arm will receive the study drug (Defibrotide) from the day of conditioning onwards. Patients allocated to the Control Arm will receive the study drug (Defibrotide) from the day that VOD is diagnosed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatic Veno-Occlusive Disease Cardiovascular Diseases Digestive System Diseases Liver Diseases Vascular Diseases

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

University Hospital, Graz, Austria

Loading trial locations.

About this study

Comparison/control intervention and duration of the intervention:

Patients will be assigned randomly to either the Defibrotide (DF) prophylaxis arm or the control arm. Those allocated to the DF prophylaxis arm (DF 25 mg/kg/d iv in 4 doses) will begin treatment at day of conditioning and stop at day +30 after Stem Cell Transplantation (SCT) or upon discharge from inpatient care. There is no dose adjustment for a patient of the study arm who developed VOD, they continue with the 25mg/kg/d iv.

Patients allocated to the control arm receive no prophylactic measures and will start DF (25 mg/kg/d iv in 4 doses) beginning at day of diagnosis of Veno-occlusive Disease (VOD) according to modified Seattle criteria. Treatment will be stopped at complete resolution of symptoms. In both arms patients who developed VOD will continue DF until:

  • complete resolution of the ascites and
  • reversion of the hepatopedal flow (if present) and
  • normalization of the total and direct bilirubin

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age <18 years
  • myeloablative conditioning and autologous or allogeneic stem cell transplantation with at least one of the following risk factors for VOD:
  • Pre-existing liver disease
  • Second myeloablative HSCT
  • History of treatment with gemtuzumab ozogamicin (MYLOTARGÒ, GO, CMA-676, Wyeth)
  • Allogeneic HSCT for leukemia beyond the second relapse
  • Osteopetrosis (OP)
  • Conditioning with busulfan and melphalan
  • Macrophage activating syndromes (MAS, like hemophagocytic lymphohistiocytosis, Griscelli, Chediak-Higashi
  • Adrenoleukodystrophy (ALD)

Exclusion criteria

  • Pregnant patients
  • Patients who are transplanted but do not fulfill any of the above mentioned criteria

Treatment and study plan

Defibrotide

Drug

Defibrotide 25 mg/kg/d

Primary outcomes

  1. The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD

    Time frame: Day + 30 post HSCT

Secondary outcomes

  1. Occurrence of Multi-System Organ Failure and Survival (all causes of mortality)

    Time frame: day +100 post HSCT

Sponsors and collaborators

Lead sponsor

European Society for Blood and Marrow Transplantation

Network

Collaborators

  • Deutsche Krebshilfe e.V., Bonn (Germany)
  • Jazz Pharmaceuticals

Registry information

Official study title

Prospective Randomized Study of the Incidence and Outcome of Veno-Occlusive Disease (VOD) With the Prophylactic Use of Defibrotide (DF) in Pediatric Stem Cell Transplantation

Acronym: VOD-DF

Important dates

Study start
2005
Primary completion
2009
Study completion
2009
First posted
Jan 9, 2006
Registry last updated
Jun 9, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.